Ardelyx Inc
ARDX6.130USD
+0.480+8.50%
收盘 11/11, 16:00（美东）报价延迟15分钟
1.49B总市值
亏损市盈率 TTM
关于 Ardelyx Inc 公司
Ardelyx, Inc. 是一家生物制药公司。该公司专注于发现、开发和商业化满足重大未满足医疗需求的先进药物。它有两种商业产品 IBSRELA（tenapanor）和 XPHOZAH。其产品线包括 RDX013 计划和 RDX020 计划。Tenapanor 是一种正在开发的小分子疗法，用于治疗或控制透析成年慢性肾病 (CKD) 患者的高磷血症或血清磷。Tenapanor 具有作用机制，在肠道局部作用以抑制钠氢交换器 3 (NHE3)。IBSRELA 是为治疗便秘型肠易激综合征 (IBS-C) 患者而开发的。XPHOZAH 是一种用于控制透析成年 CKD 患者血清磷的药物。RDX013 计划是一种用于治疗高钾血症的小分子钾促泌剂计划。 RDX020 计划是一种用于治疗代谢性酸中毒的小分子。
Ardelyx Inc简介
公司代码ARDX
公司名称Ardelyx Inc
上市日期Jun 19, 2014
CEOMr. Michael G. (Mike) Raab
员工数量395
证券类型Ordinary Share
年结日Jun 19
公司地址400 Fifth Avenue
城市WALTHAM
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编02451
电话15107451700
网址https://www.ardelyx.com/
公司代码ARDX
上市日期Jun 19, 2014
CEOMr. Michael G. (Mike) Raab
Ardelyx Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Independent Chairman of the Board
Independent Chairman of the Board
2.86M
+19.80%
Mr. Michael G. (Mike) Raab
Mr. Michael G. (Mike) Raab
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
431.46K
-9.58%
Mr. Richard J. (Rick) Rodgers
Mr. Richard J. (Rick) Rodgers
Independent Director
Independent Director
413.54K
+17.98%
Mr. Eric Foster
Mr. Eric Foster
Chief Commercial Officer
Chief Commercial Officer
298.87K
-4.87%
Mr. James P. Brady
Mr. James P. Brady
Chief Human Resources Officer
Chief Human Resources Officer
166.00K
--
Ms. Sue Hohenleitner
Ms. Sue Hohenleitner
Chief Financial Officer
Chief Financial Officer
146.90K
--
Ms. Muna Bhanji
Ms. Muna Bhanji
Independent Director
Independent Director
137.35K
+43.37%
Mr. Robert B. (Rob) Bazemore, Jr.
Mr. Robert B. (Rob) Bazemore, Jr.
Independent Director
Independent Director
41.55K
--
Dr. Merdad Parsey, M.D., Ph.D.
Dr. Merdad Parsey, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Mike Kelliher
Mr. Mike Kelliher
Chief Business Officer
Chief Business Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Independent Chairman of the Board
Independent Chairman of the Board
2.86M
+19.80%
Mr. Michael G. (Mike) Raab
Mr. Michael G. (Mike) Raab
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
431.46K
-9.58%
Mr. Richard J. (Rick) Rodgers
Mr. Richard J. (Rick) Rodgers
Independent Director
Independent Director
413.54K
+17.98%
Mr. Eric Foster
Mr. Eric Foster
Chief Commercial Officer
Chief Commercial Officer
298.87K
-4.87%
Mr. James P. Brady
Mr. James P. Brady
Chief Human Resources Officer
Chief Human Resources Officer
166.00K
--
Ms. Sue Hohenleitner
Ms. Sue Hohenleitner
Chief Financial Officer
Chief Financial Officer
146.90K
--
收入明细
FY2025Q2
FY2025Q1
FY2024
FY2024Q2
FY2024Q1
业务USD
名称
营收
占比
IBSRELA
65.05M
0.00%
XPHOZAH
25.03M
0.00%
暂无数据
业务
地区
业务USD
名称
营收
占比
IBSRELA
65.05M
0.00%
XPHOZAH
25.03M
0.00%
股东统计
更新时间: 11月6日 周四
更新时间: 11月6日 周四
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
7.54%
BlackRock Institutional Trust Company, N.A.
6.75%
Janus Henderson Investors
6.20%
Macquarie Investment Management
4.72%
Marshall Wace LLP
4.63%
其他
70.17%
持股股东
持股股东
占比
The Vanguard Group, Inc.
7.54%
BlackRock Institutional Trust Company, N.A.
6.75%
Janus Henderson Investors
6.20%
Macquarie Investment Management
4.72%
Marshall Wace LLP
4.63%
其他
70.17%
股东类型
持股股东
占比
Investment Advisor
27.73%
Investment Advisor/Hedge Fund
23.68%
Hedge Fund
11.51%
Research Firm
5.24%
Individual Investor
2.92%
Pension Fund
0.38%
Bank and Trust
0.32%
Family Office
0.08%
Private Equity
0.06%
其他
28.08%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
450
167.29M
68.85%
-25.85M
2025Q2
461
180.23M
74.79%
+5.74M
2025Q1
470
173.66M
72.61%
+2.64M
2024Q4
452
158.29M
66.42%
-9.57M
2024Q3
441
149.04M
63.31%
-41.81M
2024Q2
420
152.02M
64.97%
-36.87M
2024Q1
399
149.36M
64.27%
-40.02M
2023Q4
363
143.31M
61.82%
-29.22M
2023Q3
347
131.10M
60.21%
-55.04M
2023Q2
355
129.77M
60.57%
-68.74M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
15.98M
6.63%
+1.03M
+6.92%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
16.39M
6.8%
+512.18K
+3.23%
Jun 30, 2025
Janus Henderson Investors
15.06M
6.25%
-9.92M
-39.71%
Jun 30, 2025
Macquarie Investment Management
11.46M
4.75%
+299.42K
+2.68%
Jun 30, 2025
Marshall Wace LLP
11.25M
4.67%
+2.87M
+34.19%
Jun 30, 2025
State Street Investment Management (US)
9.84M
4.08%
-334.65K
-3.29%
Jun 30, 2025
Millennium Management LLC
11.66M
4.84%
+5.20M
+80.40%
Jun 30, 2025
Geode Capital Management, L.L.C.
5.67M
2.35%
-6.52K
-0.11%
Jun 30, 2025
BofA Global Research (US)
4.36M
1.81%
+2.70M
+161.92%
Jun 30, 2025
Nuveen LLC
3.47M
1.44%
+80.04K
+2.36%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月6日 周四
更新时间: 11月6日 周四
机构名称
占比
Virtus LifeSci Biotech Products ETF
2.47%
SPDR S&P Biotech ETF
0.45%
Invesco NASDAQ Future Gen 200 ETF
0.42%
Harbor Human Capital Factor US Small Cap ETF
0.39%
Inspire Small/Mid Cap ESG ETF
0.26%
Direxion Daily S&P Biotech Bull 3X Shares
0.23%
First Trust Small Cap Growth AlphaDEX Fund
0.15%
ProShares Ultra Nasdaq Biotechnology
0.14%
Invesco Nasdaq Biotechnology ETF
0.13%
iShares Russell 2000 Growth ETF
0.08%
查看更多
Virtus LifeSci Biotech Products ETF
占比2.47%
SPDR S&P Biotech ETF
占比0.45%
Invesco NASDAQ Future Gen 200 ETF
占比0.42%
Harbor Human Capital Factor US Small Cap ETF
占比0.39%
Inspire Small/Mid Cap ESG ETF
占比0.26%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.23%
First Trust Small Cap Growth AlphaDEX Fund
占比0.15%
ProShares Ultra Nasdaq Biotechnology
占比0.14%
Invesco Nasdaq Biotechnology ETF
占比0.13%
iShares Russell 2000 Growth ETF
占比0.08%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
